Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- University of Washington
- Study ID
- NCT04623086
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- Insulin Degludec — DRUGInsulin Degludec injection
- Insulin Glargine — DRUGInsulin Glargine injection
- Placebo — DRUG9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
Study Details
This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients. Half of the participants will receive a bridging insulin glargine dose along with the 1st dose of degludec, while other half will receive a placebo and 1st dose of degludec.
Key Dates
- Start date
- Feb 14, 2020
- Status verified
- Feb 2024
- Primary completion
- Sep 7, 2022
- Completion
- Dec 31, 2023
Study Design
- Enrollment
- 59 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Insulin Glargine and Insulin DegludecInsulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
- Placebo Comparator: Insulin Degludec and placeboInsulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
Primary Outcome Measure
Mean Change in Percent Time in Range [ Time Frame: 48 hours prior to 48 hours after 1st dose of degludec insulin ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Washington Medicine Diabetes Institute at South Lake Union | Seattle | Washington | 98109 | - |
Find similar trials in Seattle, WA
By condition
By specialty
Related Studies
- Combined Antibody Screening for Celiac and Diabetes EvaluationEnrolling By Invitation · Pacific Northwest Research Institute · Seattle, Washington
- MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 DiabetesPHASE1 · Recruiting · Kalie Tommerdahl · Aurora, Colorado
- Trial of Semaglutide for Diabetic Kidney Disease in Type 1 DiabetesPHASE2 · Recruiting · University of Washington · Aurora, Colorado
- InvesT1D: Promoting Adolescent Investment in Diabetes CareRecruiting · Harvard Pilgrim Health Care · Seattle, Washington